Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes

Comment

G Melandri. Lancet. 2001.

. 2001 Dec 8;358(9297):1997.

doi: 10.1016/S0140-6736(01)06987-2.

No abstract available

Comment on

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet. 2000 Dec 16;356(9247):2037-44. doi: 10.1016/S0140-6736(00)03400-0. Lancet. 2000. PMID: 11145489 Clinical Trial.
Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS.
Cohen M. Cohen M. Lancet. 2001 Jun 16;357(9272):1899-900. doi: 10.1016/S0140-6736(00)05088-1. Lancet. 2001. PMID: 11425405 No abstract available.
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Simoons ML; GUSTO IV-ACS Investigators. Simoons ML, et al. Lancet. 2001 Jun 16;357(9272):1915-24. doi: 10.1016/s0140-6736(00)05060-1. Lancet. 2001. PMID: 11425411 Clinical Trial.